Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $9.00 at Barclays

Sangamo Therapeutics (NASDAQ:SGMO) had its target price lifted by stock analysts at Barclays from $3.00 to $9.00 in a research note issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s price objective suggests a potential upside of 298.23% from the company’s previous close.

Several other equities research analysts have also commented on SGMO. StockNews.com initiated coverage on shares of Sangamo Therapeutics in a research report on Sunday, July 28th. They set a “sell” rating on the stock. HC Wainwright lifted their target price on Sangamo Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, November 5th.

Sangamo Therapeutics Price Performance

Shares of NASDAQ SGMO traded down $0.18 during mid-day trading on Thursday, reaching $2.26. 1,425,803 shares of the company’s stock traded hands, compared to its average volume of 6,898,806. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18. The stock has a market cap of $470.58 million, a P/E ratio of -3.17 and a beta of 1.10. The business has a 50-day simple moving average of $1.27 and a 200 day simple moving average of $0.84.

Institutional Trading of Sangamo Therapeutics

Hedge funds have recently bought and sold shares of the company. State Board of Administration of Florida Retirement System lifted its holdings in shares of Sangamo Therapeutics by 61.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 23,650 shares during the last quarter. Meritage Portfolio Management boosted its holdings in Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 6,740 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 38,850 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in Sangamo Therapeutics in the 2nd quarter worth approximately $67,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Sangamo Therapeutics in the second quarter valued at approximately $89,000. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.